ml253 has been researched along with Schizophrenia* in 1 studies
1 other study(ies) available for ml253 and Schizophrenia
Article | Year |
---|---|
Discovery of a selective M₄ positive allosteric modulator based on the 3-amino-thieno[2,3-b]pyridine-2-carboxamide scaffold: development of ML253, a potent and brain penetrant compound that is active in a preclinical model of schizophrenia.
Herein we report a next generation muscarinic receptor 4 (M(4)) positive allosteric modulator (PAM), ML253 which exhibits nanomolar activity at both the human (EC(50)=56 nM) and rat (EC(50)=176 nM) receptors and excellent efficacy by the left-ward shift of the ACh concentration response curve (fold shift, human=106; rat=50). In addition, ML253 is selective against the four other muscarinic subtypes, displays excellent CNS exposure and is active in an amphetamine-induced hyperlocomotion assay. Topics: Allosteric Regulation; Amides; Animals; Brain; Cholinergic Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Half-Life; Humans; Protein Binding; Pyridines; Rats; Receptor, Muscarinic M4; Schizophrenia; Structure-Activity Relationship; Thiophenes | 2013 |